Skip to content
Clinical trial

Efficacy of Lumateperone 42 mg in Major Depressive Disorder: Subgroup Analysis of a Phase 3 Randomized, Placebo-Controlled Trial.

Nov 2026 · The Primary Care Companion For CNS Disorders · Vol 28 6 · 0 citations
Medicine

Abstract

Objective: Lumateperone is an FDA-approved atypical antipsychotic to treat schizophrenia, bipolar I or II depression, and major depressive disorder (MDD). Post hoc analyses of a randomized, phase 3, double-blind, placebo-controlled trial (Study 501) evaluated the efficacy of lumateperone 42 mg adjunctive to antidepressant therapy (ADT) in demographic and clinical subgroups of patients with MDD with inadequate ADT response. Methods: Adults with DSM-5 criteria for MDD with inadequate response to 1-2 courses of ADT, Montgomery- Åsberg Depression Rating Scale (MADRS) Total score ≥24, Clinical Global Impression Scale-Severity (CGI-S) score ≥4, and Quick Inventory of Depressive Symptomatology-Self-Report 16-item (QIDS-SR-16) score ≥14 were randomized 1:1 to 6-week oral lumateperone 42 mg+ADT or placebo+ADT. Efficacy was evaluated in the overall population and patient subgroups by demographic (age, sex, race, ethnicity, and region) and baseline disease characteristics (MADRS Total score, ADT type, number of ADT failures [in current episode and lifetime], and presence of anxious distress). Results: The modified intent-to-treat population comprised 481 patients (lumateperone+ADT, n = 239; placebo+ADT, n = 242). Lumateperone+ADT significantly improved MADRS Total score (least squares mean difference [LSMD], -4.9; P < .0001), CGI-S score (LSMD, -0.7; P < .0001), and QIDS-SR-16 Total score (LSMD, -2.4; P < .0001) at Day 43 versus placebo+ADT. Lumateperone+ADT significantly improved MADRS Total score (P < .01) across all demographic subgroups and baseline disease severity versus placebo+ADT. Significant improvements (P < .05) in CGI-S, QIDS-SR-16 Total scores, and MADRS response and remission rates were also observed across most subgroups. Conclusion: Lumateperone+ADT demonstrated robust efficacy over placebo+ADT across a broad range of demographic and clinical subgroups of patients with MDD. Clinical Trials Registration. ClinicalTrials.gov identifier: NCT04985942. Prim Care Companion CNS Disord 2026;28(6):26m04289. Author affiliations are listed at the end of this article.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.